ViewRay Revenue and Competitors

MRI-GUIDED ADAPTIVE RADIOTHERAPY ViewRay®, Inc. (NASDAQ:VRAY), designs, manufactures, and markets the MRIdian® radiation therapy system to address the key limitations of existing external-beam radiation therapy technologies. MRIdian employs MRI-based technology to provide real-time imaging that clearly defines the targeted tumor from the surrounding soft tissue and other critical organs during radiation treatment. MRIdian allows physicians to record the level of radiation exposure that the tumor has received and adapt the prescription as needed. ViewRay believes this combination of enhanced visualization, on-line adapting and accurate dose recording will significantly improve the safety and efficacy of radiation therapy, leading to better outcomes for patients. At ViewRay, our vision is clear. We're dedicated to giving doctors new and better ways to treat cancer with radiation therapy. We're an entrepreneurial company with big ambitions, unlimited potential and a passion for improving the lives of patients with cancer. We're always on the lookout for talented people who share our commitment and values. Contact us if you're enthusiastic about working with a close-knit team and motivated by the prospect of making a difference.

keywords:Biotechnology,Healthcare,Medical Devices,Pharmaceuticals